Please Wait.....
Report
Doxorubicin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 130 Pages I Mordor Intelligence
Doxorubicin Market Analysis
The global doxorubicin market is valued at USD 1.22 billion in 2025 and is projected to reach USD 1.67 billion by 2030, registering a 6.50% CAGR over the forecast period. Robust clinical evidence keeps the agent at the center of many oncology protocols, and continuous advances in liposomal delivery expand its therapeutic window. Sustained cancer prevalence, wider generic availability, and targeted formulation innovations are reinforcing demand even as high-cost biologics compete for market share. At the same time, cardiotoxicity concerns, stricter hazardous-drug handling rules, and workflow shifts toward specialty pharmacy models temper longer-term uptake.
Global Doxorubicin Market Trends and Insights
Escalating Global Cancer Burden Elevating Chemotherapy Volumes
Rising worldwide cancer incidence is driving persistent use of broad-spectrum cytotoxics such as doxorubicin. Even as precision biologics proliferate, clinicians continue to rely on anthracycline-taxane combinations for breast tumors with high recurrence scores, showing superior survival versus taxane monotherapy in recent Phase 3 data presented at the San Antonio Breast Cancer Symposium. Versatility across solid and hematologic indications expands procedure volumes, reinforcing the doxorubicin market despite premium biologic entrants.
Growing Availability of Affordable Generic & Liposomal Doxorubicin
Intensifying generic competition is widening patient access and pressuring prices. New entrants such as Lupin introduced doxorubicin hydrochloride liposome injection in the United States in August 2024, enlarging the liposomal category and catalyzing broader adoption in budget-constrained health systems. This influx of lower-priced alternatives supports treatment equity in Asia-Pacific and Latin America, further stimulating doxorubicin market growth.
Cumulative Cardiotoxicity Risk Necessitating Strict Dose Caps & Monitoring
Anthracycline-induced cardiomyopathy limits lifetime exposure, with cumulative dose caps of 450-550 mg/m enshrined in guidelines. Although dexrazoxane offers partial protection, no other FDA-approved cardioprotective agent exists, forcing prescribers to juggle efficacy and long-term cardiac safety. This restraint slows repeat-cycle utilization within the doxorubicin market, spurring innovation in safer delivery platforms.
Other drivers and restraints analyzed in the detailed report include:
Technological Progress in Liposomal & Nanocarrier Delivery / Government-Led Cancer Care Expansion Programs in Emerging Markets / Shift Toward Targeted Therapies and Immuno-Oncologics Displacing Anthracyclines /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Conventional injection maintained a 52% revenue contribution to the doxorubicin market in 2024, anchored in decades of clinical familiarity and competitive generic pricing. Pegylated liposomal doxorubicin, while only a fraction of earlier volume, is expanding at a 7.5% CAGR and is pivotal to enlarging the doxorubicin market size owing to reduced cardiac toxicity and prolonged circulation time. Regulatory approvals for advanced carriers such as Myocet and Celdoxome in Europe underscore a growing consensus that lipid-based vectors can safely extend cumulative dose ceilings. Research on pH-triggered nanocarriers and thermosensitive liposomes reveals promising preclinical data, suggesting that co-development of device-based hyperthermia triggers could structurally differentiate future entrants and compound competitive intensity in this formulation segment.
Continued supply stability of lyophilized powder formulations protects treatment access in regions lacking sophisticated cold chains, particularly parts of Africa and rural South America. Volume demand here, though modest, provides durable revenue streams for manufacturers with cost-focused portfolios inside the broader doxorubicin market.
The Doxorubicin Market Report is Segmented by Drug Formulation (Conventional Doxorubicin Injection (Solution), Lyophilized Powder for Reconstitution, and More), Application (Bladder Cancer, Ovarian Cancer, and More), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online / E-Commerce Pharmacy), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Geography Analysis
North America remained the anchor geography with 48% of global revenue in 2024. Inpatient reimbursement structures, broad insurance coverage, and early adoption of cardioprotective delivery systems safeguard volume. Value-based contracts tying payments to progression-free survival may modify pricing headroom, yet the switch to liposomal variants is likely to sustain stable dollar growth for the regional doxorubicin market.
Asia-Pacific is set to be the principal acceleration engine, advancing at 8.3% CAGR to 2030. Rising diagnostic penetration, burgeoning private insurance pools in China and India, and government incentives for local manufacturing underpin robust demand. Sun Pharmaceutical Industries' oncology build-out via acquisitions such as the USD 355 million Checkpoint Therapeutics deal shows local players' intent to climb the innovation ladder. Indigenous production, combined with regulatory fast-tracking, is expected to shrink time-to-market for new formulations and entrench regional suppliers inside the doxorubicin market.
Europe benefits from a sophisticated reimbursement apparatus but faces budget constraints that favor generics. EMA approvals for multiple liposomal options diversify clinician choice yet subject pricing to national tender pressures. South America holds latent potential, particularly Brazil, where oncology hospital expansion and biosimilar uptake broaden patient throughput. Improvement in domestic fill-finish capabilities could lower import dependencies and stimulate localized segments of the doxorubicin market.
List of Companies Covered in this Report:
Johnson&Johnson / Sun Pharmaceuticals Industries / Pfizer / Baxter / Teva Pharmaceutical Industries / Cadila Pharmaceuticals Ltd / Cipla / Dr. Reddy's Laboratories / Hikma Pharmaceuticals / Viatris (Mylan) / Accord Healthcare / Intas Pharmaceutical / Fresenius / Celon Laboratories / Zhejiang Hisun Pharmaceutical Co. / Nantong Jinghua Pharmaceutical Co. / Lupin / TTY Biopharm Co. Ltd / Sandoz Group /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Escalating Global Cancer Burden Elevating Chemotherapy Volumes
4.2.2 Growing Availability of Affordable Generic & Liposomal Doxorubicin
4.2.3 Technological Progress in Liposomal & Nanocarrier Delivery Enhancing Therapeutic Index
4.2.4 Government-Led Cancer Care Expansion Programs in Emerging Markets
4.2.5 Rising Adoption of Combination Regimens Featuring Doxorubicin for Hematologic Malignancies
4.3 Market Restraints
4.3.1 Cumulative Cardiotoxicity Risk Necessitating Strict Dose Caps & Monitoring
4.3.2 Shift Toward Targeted Therapies and Immuno-oncologics Displacing Anthracyclines
4.3.3 Stringent Hazardous-Drug Handling Standards Raising Distribution Costs
4.4 Supply-Chain Analysis
4.5 Porter's Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitutes
4.5.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Drug Formulation
5.1.1 Conventional Doxorubicin Injection (Solution)
5.1.2 Lyophilized Powder for Reconstitution
5.1.3 Pegylated Liposomal Doxorubicin (PLD)
5.1.4 Non-Pegylated Liposomal Doxorubicin
5.2 By Application (Cancer Type)
5.2.1 Breast Cancer
5.2.2 Ovarian Cancer
5.2.3 Leukemia
5.2.4 Lymphoma
5.2.5 Bladder Cancer
5.2.6 Kaposi Sarcoma
5.2.7 Multiple Myeloma
5.2.8 Gastric Cancer
5.3 By Distribution Channel
5.3.1 Hospital Pharmacy
5.3.2 Retail Pharmacy
5.3.3 Online / E-commerce Pharmacy
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 South Korea
5.4.3.5 Australia
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
6.3.1 Johnson & Johnson (Janssen)
6.3.2 Sun Pharmaceutical Industries Ltd
6.3.3 Pfizer Inc.
6.3.4 Baxter International Inc.
6.3.5 Teva Pharmaceutical Industries Ltd
6.3.6 Cadila Pharmaceuticals Ltd
6.3.7 Cipla Ltd
6.3.8 Dr. Reddy's Laboratories Ltd
6.3.9 Hikma Pharmaceuticals PLC
6.3.10 Viatris (Mylan)
6.3.11 Accord Healthcare
6.3.12 Intas Pharmaceuticals Ltd
6.3.13 Fresenius Kabi AG
6.3.14 Celon Laboratories Pvt Ltd
6.3.15 Zhejiang Hisun Pharmaceutical Co.
6.3.16 Nantong Jinghua Pharmaceutical Co.
6.3.17 Lupin Limited
6.3.18 TTY Biopharm Co. Ltd
6.3.19 Sandoz AG
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security